31
Participants
Start Date
August 1, 2007
Primary Completion Date
April 1, 2009
Study Completion Date
May 1, 2009
Apremilast
20 mg PO (by mouth) twice per day (BID) for 84 days and then an additional 84 days during the optional treatment extension period. For subjects meeting the dose escalation criteria, dosage during the optional treatment extension period can be increased to 30 mg BID.
Central Dermatology, St Louis
Oregon Medical Research Center, P.C., Portland
Tufts-New England Medical Center Hospitals, Boston
Baylor Research Institute, Dallas
Lead Sponsor
Amgen
INDUSTRY